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Background
Genetically engineered T cells have broadened the
opportunity for use of T cell immunotherapy in cancer
patients. The possibility of improving T cell efficacy via
introduction of additional genes potentially gives them
an advantage over TIL. Studies in adoptive T cell transfer
suggest that persistence is fundamental to the efficacy of
this therapy. This Phase I clinical trial uses TCR TIL
1383I transduced T cells to target the tyrosinase antigen
on melanoma cells. Two of the objectives in this clinical
trial in stage IV melanoma patients include measuring
persistence and monitoring the behavior of tumor-
reactive T cells in vivo.
Methods
Stage IV melanoma patients must have tumors that are
positive for both HLA-A2 and tyrosinase on pathologic
review. Peripheral blood mononuclear cells (PBMCs) are
isolated from the patients and activated with anti-hCD3,
rhIL2 and rhIL15. These PBMCs are transduced with len-
tivirus encoding the TIL 1383I TCR and expanded to
treatment numbers. The transduced cells are suspended in
5% human albumin and infused over 30 minutes. The
infusion is preceded by lymphodepletion with fludarabine
and cyclophosphamide and followed with low dose
IL-2 for one week. A modified CD34 cassette in the
vector enables monitoring of the transduced T cells in
the patient’s PBMC post-infusion. PBMCs, complete
metabolic panels, lactate dehydrogenase, and complete
blood counts are collected on days 1, 3, 5, 7, 14, 25, 35
and monthly up to 3 months, and then every 1-3 months
as clinically indicated. Physical exams, toxicity assessment,
whole body PET/CT or CT scans, Audiology and
Ophthalmologic exams are performed pretreatment and at
4 weeks post infusion and as clinically indicated every 1-3
months afterwards.
The presence of transduced T cells at each time point is
measured by staining with anti-CD34 mAb and analyzed
using a BD LSRFortessa flow cytometer.
Conclusion
This study is open to accrual at Loyola University Medical
Center and is in the process of expanding to other institu-
tions. We have successfully completed treatment in 3 of
55 screened patients, with goal accrual of 24 patients.
Results to date confirm that infused genetically engineered
TIL 1383I TCR transduced T cells are detectable more
than 6 months after infusion and demonstrate activity. We
plan to move forward with a Phase II study.
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